Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?
about
Feasibility and Outcome of HCV Treatment in a Canadian Federal Prison PopulationHepatitis C virus infection in san francisco’s HIV-infected urban poorMorphine Withdrawal Enhances Hepatitis C Virus Replicon ExpressionInterferon alpha therapy for hepatitis C: treatment completion and response rates among patients with substance use disordersMorphine Enhances Hepatitis C Virus (HCV) Replicon ExpressionUpregulation of SOCS-3 and PIAS-3 Impairs IL-12-Mediated Interferon-Gamma Response in CD56+ T Cells in HCV-Infected Heroin UsersBest strategies for global HCV eradication.Diagnosis, management, and treatment of hepatitis C: an updateInfectious disease comorbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis.Addressing the HIV-related needs of substance misusers in New York State: the benefits and barriers to implementing a "one-stop shopping" model.A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment.Drug treatment program patients' hepatitis C virus (HCV) education needs and their use of available HCV education services.HIV/hepatitis prevention in drug abuse treatment programs: guidance from researchHepatitis C management by addiction medicine physicians: results from a national surveyTreatment of hepatitis C virus infectionEarly prediction of major depression in chronic hepatitis C patients during peg-interferon alpha-2b treatment by assessment of vegetative-depressive symptoms after four weeksAre there national strategies, plans and guidelines for the treatment of hepatitis C in people who inject drugs? A survey of 33 European countries.Antiviral completion rates and sustained viral response in hepatitis C patients with and without preexisting major depressive disorderBarriers to the treatment of hepatitis C. Patient, provider, and system factors.Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users.Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug usersPrevention and treatment of hepatitis C in injection drug users.Characteristics and impact of methamphetamine use in patients with chronic hepatitis CTherapeutic challenges in hepatitis C-infected injection drug using patients.Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection.Hepatitis infection in the treatment of opioid dependence and abuse.Heroin use promotes HCV infection and dysregulates HCV-related circulating microRNAs.Substance abuse treatment and receipt of liver specialty care among persons coinfected with HIV/HCV who have alcohol problemsAn international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential.Association between hepatitis C virus and opioid use while in buprenorphine treatment: preliminary findingsCo-occurring Hepatitis C, substance use, and psychiatric illness: treatment issues and developing integrated models of care.Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada.Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory.Illicit opioid use in Canada: comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study).Hepatitis C treatment eligibility and comorbid medical illness in methadone maintenance (MMT) and non-MMT patients: a case-control studyFactors associated with interest in initiating treatment for hepatitis C Virus (HCV) infection among young HCV-infected injection drug users.Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program.Hepatitis C screening: getting it right.Psychiatric behavioral aspects of comanagement of hepatitis C virus and HIVHepatitis C in people with mental illness: how big is the problem and how do we respond?
P2860
Q27473164-3E18A248-3DDC-4C62-AF48-843EE74D61E1Q27473306-D609138C-8670-4972-903E-0B2E55EBD876Q27477516-BA2BFA63-48D8-4138-B8A4-5BCCADCCBCD3Q27477998-8E1E8CBF-DAE9-424D-AF7C-ED22A982C4DFQ27478396-90E90CC2-BE73-4C18-8718-2B4F16659F88Q27491026-780B7236-D3CC-4539-ADB2-6D1BFB6A89D9Q27693824-B03B74DD-40B9-4347-A744-95785DEE70B8Q29619682-AF07ABD7-B6B7-4686-9068-5C488D4EE36FQ30395708-E85DAB04-7A87-4B00-8012-C6A54152D341Q30399447-E52E1B8E-0BBD-41FD-8505-7F7CCF80BA21Q30540697-8187626F-F539-4A65-8A58-5E02B755271AQ33277431-F01F16C7-6BA6-4471-BAF6-32888D3868FEQ33774978-18DBEE00-CCBE-493E-96FF-8645B645D621Q34090853-EBE980F0-F7E4-424F-B06D-A4E11D5F3CD9Q34099424-12324C01-1874-46EC-B492-0D43E4116148Q34225384-11F4E2E6-0397-4108-8607-9FE72BEB79BFQ34260584-D95C2D15-2C6B-4BE4-AE50-3FC0EA627422Q34330471-9984DD79-A56E-4F29-AE87-CA45FC0C2999Q34723678-392A6708-AFC8-4B50-888C-9AB127457E0BQ34795051-C1EDE811-CAC6-4D11-8802-47F42CB4BEB8Q34795057-7473FF33-01A9-473E-B8AB-E32F95F24B54Q34984130-82992A26-C2DA-45BB-AEAF-47CF128FCA3EQ35116890-35F79E59-9D9E-4AEE-A475-1FD71BCC7129Q35171905-C44BF245-4654-452F-A42F-A5F9B6453922Q35205389-2044B0E2-9A51-432F-8F02-CF22B06C5543Q35389163-64CC3E1C-5DAB-4DBC-A97C-EBC06E3008BBQ35650384-E3C3FBD5-3E43-49B9-8E42-383AB709CC50Q36016477-74393427-B8C2-403E-B7B4-6D0BC42E98AFQ36090175-00CAE0C9-8793-4CF9-8478-9A414D24992CQ36263653-D7E70476-778A-47A8-9F4F-3651E5957411Q36272273-7160DA24-6BDB-4E49-94E0-26D421C3FD01Q36272393-0069883A-19CE-4F30-A19B-AD670BA52126Q36274123-6804F491-2BF4-4B21-B038-496057400E77Q36274331-55167E96-54F2-41F6-B75F-13D9025723DBQ36296251-C11DCA83-53F0-4FCD-B2E2-8182B6D550E7Q36376962-7F4E7EE7-942D-41FC-A91A-CFE43BDA1ECAQ36421892-10504675-9C93-46C5-9486-208F90386C1BQ36575211-E63D779C-7431-4835-8145-4B2B5828D0EFQ36619816-07B4001A-1FB6-4A7C-A6AD-AE5E7D772123Q36658219-772273EC-C3CC-40E0-A239-149D258DF8F6
P2860
Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?
@ast
Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?
@en
Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?
@nl
type
label
Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?
@ast
Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?
@en
Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?
@nl
prefLabel
Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?
@ast
Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?
@en
Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?
@nl
P2093
P2860
P1476
Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?
@en
P2093
D H Ciccarone
P2860
P304
P356
10.1056/NEJM200107193450311
P407
P577
2001-07-01T00:00:00Z